Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;23(6):963-972.
doi: 10.1111/psyg.13017. Epub 2023 Sep 6.

Clozapine for the treatment of aggressiveness and agitation in advanced dementia

Arwed E Michael  1 , Nikolaus Michael  2   3 , Andreas Erfurth  3   4 , Milenko Kujovic  5
Affiliations

Clozapine for the treatment of aggressiveness and agitation in advanced dementia

Arwed E Michael et al. Psychogeriatrics. 2023 Nov.

Abstract

Background: Distressing behavioural symptoms, particularly agitation and aggressiveness, remain a difficult problem in everyday clinical practice in the treatment of multimorbid patients with dementia. Clozapine may be an effective therapeutic alternative in this context.

Methods: In a retrospective study, patients who had a diagnosis of dementia and had been treated in a specialized geriatric psychiatry unit with clozapine between August 2018 and February 2022 were included, and medical records were systematically reviewed. The Clinical Global Impressions Scale was used to assess improvement, and the Pittsburgh Agitation Scale for symptom reduction. In addition, side effects and clinical features were documented in detail.

Results: A total of 31 patients (median age 82 years) were identified with a mean clozapine dose of 47.2 (SD 35.6) mg. A total of 13 patients tolerated clozapine very well, 10 showed tolerable side effects, and in 10 patients side effects were the reason for stopping clozapine. Behavioural symptoms improved significantly, as indicated by the assessment scores.

Conclusions: In summary, clozapine was effective and well tolerated in 23 patients, suggesting that low-dose clozapine may help to alleviate the suffering of difficult-to-treat multimorbid patients with advanced dementia and their caregivers. However, particular attention should be paid to adverse drug reactions, especially in patients with cardiovascular and pulmonary impairment.

Keywords: Alzheimer dementia; antipsychotic drugs; disruptive behaviour; vascular dementia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scores of the Pittsburgh Agitation Scale (PAS) before and after clozapine (CLZ).
See this image and copyright information in PMC

References

    1. GBD 2016 Neurology Collaborators . Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 459–480. - PMC - PubMed
    1. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and Management of Dementia: review. JAMA 2019; 322: 1589–1599. - PMC - PubMed
    1. Deardorff WJ, Grossberg GT. Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia. Handb Clin Neurol 2019; 165: 5–32. - PubMed
    1. Meyer JM, Cummings MA, Proctor G, Stahl SM. Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am 2016; 39: 541–556. - PubMed
    1. Wirz‐Justice A, Werth E, Savaskan E, Knoblauch V, Gasio PF, Müller‐Spahn F. Haloperidol disrupts, clozapine reinstates the circadian rest‐activity cycle in a patient with early‐onset Alzheimer disease. Alzheimer Dis Assoc Disord 2000; 14: 212–215. - PubMed